Form 4: Verona Pharma's General Counsel, Andrew Fisher, Acquires 300,000 Ordinary Shares Through RSU Award

Andrew Fisher, General Counsel of Verona Pharma plc, reports the acquisition of 300,000 ordinary shares through a Restricted Share Unit (RSU) award on October 30, 2024.

Summary

• On October 30, 2024, Andrew Fisher, the General Counsel of Verona Pharma plc, acquired 300,000 ordinary shares of the company.
• This acquisition was through an award of Restricted Share Units (RSUs).
• Each RSU represents a contingent right to receive one ordinary share of Verona Pharma.
• The RSUs vest over four years, with 1/4th vesting on November 1, 2025, and the remaining balance vesting in 12 equal quarterly installments thereafter.
• Following the transaction, Fisher beneficially owns 300,000 ordinary shares underlying the RSUs, which are represented by 37,500 American Depositary Shares (ADSs), with each ADS representing eight ordinary shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, indicating confidence in the company's future, but doesn't represent a major event.

Positives

• The RSU award aligns the General Counsel's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and contribution over the next four years.

Future Outlook

The vesting schedule of the RSUs indicates a commitment to the company's future over the next four years.

Industry Context

This type of equity compensation is common in the pharmaceutical industry to incentivize key executives and align their interests with shareholders.

Comparison to Industry Standards

• RSU grants are a standard form of executive compensation in the pharmaceutical industry, often used by companies like Pfizer, Johnson & Johnson, and Novartis to attract and retain talent.
• Vesting schedules of four years with quarterly installments are also typical, aligning with long-term strategic goals.

Stakeholder Impact

• The RSU award aligns management's interests with shareholders, potentially driving long-term value creation.

Key Dates